Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine

Graphical abstract Highlights ► Nasal NV VLP dry powder mucoadhesive-containing formulation induces systemic and mucosal immunity. ► Mucoadhesive-containing dry powder formulation stabilizes the norovirus VLP antigen. ► Mucoadhesive nasal dry powder vaccine exhibits superior immunogenicity over liqu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2011-07, Vol.29 (32), p.5221-5231
Hauptverfasser:	Velasquez, Lissette S, Shira, Samantha, Berta, Alice N, Kilbourne, Jacquelyn, Medi, Babu M, Tizard, Ian, Ni, Yawei, Arntzen, Charles J, Herbst-Kralovetz, Melissa M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Administration, Intranasal agonists Allergy and Immunology Aloe vera Animals Antibodies, Viral - immunology Antibody Formation antigens Applied microbiology Biological and medical sciences blood serum Caliciviridae Infections - prevention & control Cell culture Cell Line FDA approval Female Fundamental and applied biological sciences. Psychology gelation Guinea Pigs Humans immune response Immune system immunization Immunogenicity Influenza Intranasal delivery Mice Microbiology Microscopy, Electron Miscellaneous Mucoadhesive Mucous Membrane - immunology Norovirus Norovirus - immunology Norovirus vaccine nose Polysaccharides Powders Rats Spray dry powder formulation Studies TLR agonist vaccine development Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Virus-Like Particle - administration & dosage Vaccines, Virus-Like Particle - immunology Vaccines, Virus-Like Particle - ultrastructure Virology virus-like particles Virus-like particles (VLP)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Graphical abstract Highlights ► Nasal NV VLP dry powder mucoadhesive-containing formulation induces systemic and mucosal immunity. ► Mucoadhesive-containing dry powder formulation stabilizes the norovirus VLP antigen. ► Mucoadhesive nasal dry powder vaccine exhibits superior immunogenicity over liquid formulation with adjuvant. ► Mucoadhesive delays mucociliary clearance in the nasal cavity, but is not immunostimulatory. ► The nasal dry powder formulation offers needle-free administration and better vaccine stability.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2011.05.027